Analytical Data
-
Gene name
SF3B3
- Application
-
Alternative Names
Splicing factor 3B subunit 3(Pre-mRNA-splicing factor SF3b 130 kDa subunit)(SF3b130)(Spliceosome-associated protein 130)(SAP 130)
-
Species
Bovine
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0JN52
-
Expression Region
860-1186aa
-
Molecular Weight
42.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SF3B3 is a critical component of the spliceosomal complex, which plays a pivotal role in the pre-mRNA splicing process that is essential for the maturation of eukaryotic mRNA. The protein is part of the SF3B complex, which is involved in the recognition and selection of splice sites during the splicing of pre-mRNA. Due to its essential role in gene expression regulation, SF3B3 has garnered significant attention in the context of various diseases, particularly cancer, where aberrant splicing is often observed. Research has shown that mutations and alterations in the splicing machinery, including components like SF3B3, can lead to the production of oncoproteins or the loss of tumor suppressor isoforms, thereby contributing to tumorigenesis. Additionally, SF3B3 has been implicated in the resistance mechanisms of certain cancer treatments, highlighting the necessity for a deeper understanding of its function and interactions. Moreover, studies on the recombinant form of SF3B3 can provide insights into its structural and functional properties, enabling the development of targeted therapies that modulate splicing processes. Overall, the comprehensive study of SF3B3, including its recombinant expression and characterization, is crucial for elucidating its role in cellular mechanisms and its potential as a therapeutic target in cancer and other splicing-related disorders.
